208 related articles for article (PubMed ID: 30262672)
21. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
22. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
23. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
25. Statin use and hip fractures in U.S. kidney transplant recipients.
Vangala C; Lenihan CR; Montez-Rath ME; Nair SS; Navaneethan SD; Ramanathan V; Winkelmayer WC
BMC Nephrol; 2017 May; 18(1):145. PubMed ID: 28460645
[TBL] [Abstract][Full Text] [Related]
26. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
27. Association of Proton Pump Inhibitor/Histamine-2 Blocker Use and Ocular Toxoplasmosis: Findings from a Large US National Database.
Conrady CD; Pradeep T; Yu Y; Johnson MW; VanderBeek BL
Ophthalmol Retina; 2023 Mar; 7(3):261-265. PubMed ID: 36058521
[TBL] [Abstract][Full Text] [Related]
28. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
29. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
30. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
Adams AL; Black MH; Zhang JL; Shi JM; Jacobsen SJ
Ann Epidemiol; 2014 Apr; 24(4):286-90. PubMed ID: 24507954
[TBL] [Abstract][Full Text] [Related]
31. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
34. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
35. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
38. Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study.
Nakashima A; Ohkido I; Yokoyama K; Mafune A; Urashima M; Yokoo T
PLoS One; 2015; 10(11):e0143656. PubMed ID: 26618538
[TBL] [Abstract][Full Text] [Related]
39. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD
CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179
[TBL] [Abstract][Full Text] [Related]
40. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
